Moody’s assigns PharmzZell B2

Moody’s Investors Service said it assigned a B2 corporate family rating and a B2-PD probability of default rating to European Medco Development 3 Sarl (PharmaZell) the holding company at the top of the restricted group and at which the group will provide consolidated reports going forward.

Concurrently, Moody’s assigned B2 instrument ratings to the €290 million senior secured term loan B maturing in May 2027 and the €75 million senior secured revolving facility maturing in November 2026 issued by European Medco Development 4 Sarl, a subsidiary of PharmaZell.

The proceeds from the new facilities will help finance the group’s acquisition by financial sponsor Bridgepoint.

The outlook is stable.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.